FR2385688B1 - - Google Patents

Info

Publication number
FR2385688B1
FR2385688B1 FR7808850A FR7808850A FR2385688B1 FR 2385688 B1 FR2385688 B1 FR 2385688B1 FR 7808850 A FR7808850 A FR 7808850A FR 7808850 A FR7808850 A FR 7808850A FR 2385688 B1 FR2385688 B1 FR 2385688B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7808850A
Other languages
French (fr)
Other versions
FR2385688A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of FR2385688A1 publication Critical patent/FR2385688A1/fr
Application granted granted Critical
Publication of FR2385688B1 publication Critical patent/FR2385688B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/16Somatostatin; related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/26Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7808850A 1977-03-28 1978-03-28 Nouveaux peptides a activite biologique Granted FR2385688A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/781,580 US4105603A (en) 1977-03-28 1977-03-28 Peptides which effect release of hormones

Publications (2)

Publication Number Publication Date
FR2385688A1 FR2385688A1 (fr) 1978-10-27
FR2385688B1 true FR2385688B1 (enExample) 1983-10-07

Family

ID=25123228

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7808850A Granted FR2385688A1 (fr) 1977-03-28 1978-03-28 Nouveaux peptides a activite biologique

Country Status (19)

Country Link
US (1) US4105603A (enExample)
JP (1) JPS53130687A (enExample)
AT (1) AT366026B (enExample)
AU (1) AU519122B2 (enExample)
BE (1) BE865380A (enExample)
CA (1) CA1102314A (enExample)
CH (1) CH639361A5 (enExample)
DE (1) DE2813327A1 (enExample)
DK (1) DK131878A (enExample)
ES (1) ES468241A1 (enExample)
FI (1) FI780907A7 (enExample)
FR (1) FR2385688A1 (enExample)
GB (1) GB1564191A (enExample)
IE (1) IE46862B1 (enExample)
IT (1) IT1105152B (enExample)
LU (1) LU79320A1 (enExample)
NL (1) NL7803289A (enExample)
SE (1) SE446190B (enExample)
ZA (1) ZA781599B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211693A (en) * 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
US4185010A (en) * 1978-12-12 1980-01-22 American Home Products Corporation Nonapeptides
US4225472A (en) * 1979-05-29 1980-09-30 American Home Products Corporation Truncated somatostatin analogs
USRE30548E (en) * 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
FR2523125A1 (fr) * 1982-03-08 1983-09-16 Sanofi Sa Analogues de la somatostatine a activite biologique modifiee et medicaments en contenant
US4428942A (en) 1982-05-17 1984-01-31 The Salk Institute For Biological Studies Analogs of somatostatin
US4443368A (en) * 1982-11-01 1984-04-17 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
ATE122357T1 (de) * 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
DE60014919T2 (de) * 1999-08-06 2005-10-13 Genentech, Inc., South San Francisco Peptidantagonisten des faktors viia
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) * 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
MXPA06003014A (es) * 2003-09-18 2006-06-23 Raven Biotechnologies Inc Kid3 y anticuerpos de kid3 que se unen a este.
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト,インコーポレイテッド トランスフェリンレセプター抗体
EP1796718A2 (en) * 2004-10-05 2007-06-20 Genentech, Inc. Therapeutic agents with decreased toxicity
WO2006076584A2 (en) 2005-01-12 2006-07-20 Raven Biotechnologies, Inc. Kid31 and antibodies that bind thereto
CA2596115A1 (en) * 2005-01-31 2006-08-10 Raven Biotechnologies, Inc. Luca2 and antibodies that bind thereto
US7674619B2 (en) * 2005-02-02 2010-03-09 Mather Jennie P ADAM-9 modulators
US20060171952A1 (en) * 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
EP1846455A4 (en) * 2005-02-03 2010-02-17 Raven Biotechnologies Inc ANTIBODY TO THE ONKOSTATIN M RECEPTOR
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
HRP20190756T1 (hr) 2011-05-21 2019-06-14 Macrogenics, Inc. Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3
ES2610779T3 (es) 2011-08-23 2017-05-03 President And Fellows Of Harvard College Nanopartículas de péptidos y usos de las mismas
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SI2968520T1 (sl) 2013-03-14 2022-01-31 Macrogenics, Inc. Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
EP2978438A1 (en) 2013-03-29 2016-02-03 Centre National de la Recherche Scientifique (C.N.R.S.) Cgrp receptor agonist for hiv treatment or prevention
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
CA2974807A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CR20200423A (es) 2015-07-30 2021-01-20 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
HK1251475A1 (zh) 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
GEAP202214922A (en) 2016-04-15 2022-02-10 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904594A (en) * 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
US3917578A (en) * 1973-12-10 1975-11-04 Ayerst Mckenna & Harrison Process for producing somatostatin and intermediates
US3882098A (en) * 1974-01-03 1975-05-06 American Home Prod Synthesis of des-Ala{hu 1{b , Gly{hu 2{b , Asn{hu 5{b -SRIF and intermediates
US4011207A (en) * 1974-12-27 1977-03-08 American Home Products Corporation Des-(Ala1, Gly2,Lys4 -Srif, Des-(Ala1, Gly2, Lys4)-D-Trp8 -Srif and intermediates
US3933784A (en) * 1975-01-27 1976-01-20 American Home Products Corporation Des-(ser13)-srif and intermediates

Also Published As

Publication number Publication date
AU3430778A (en) 1979-09-27
US4105603A (en) 1978-08-08
GB1564191A (en) 1980-04-02
CH639361A5 (de) 1983-11-15
IT1105152B (it) 1985-10-28
FR2385688A1 (fr) 1978-10-27
BE865380A (fr) 1978-07-17
FI780907A7 (fi) 1978-09-29
IT7848586A0 (it) 1978-03-23
DE2813327A1 (de) 1978-10-05
JPS53130687A (en) 1978-11-14
AT366026B (de) 1982-03-10
DE2813327C2 (enExample) 1988-08-18
ZA781599B (en) 1979-10-31
IE780511L (en) 1978-09-28
LU79320A1 (fr) 1978-06-29
ATA213878A (de) 1981-07-15
CA1102314A (en) 1981-06-02
SE7803318L (sv) 1978-09-29
IE46862B1 (en) 1983-10-19
NL7803289A (nl) 1978-10-02
SE446190B (sv) 1986-08-18
DK131878A (da) 1978-09-29
JPS6141920B2 (enExample) 1986-09-18
ES468241A1 (es) 1978-12-01
AU519122B2 (en) 1981-11-12

Similar Documents

Publication Publication Date Title
FR2385688B1 (enExample)
FR2377047B3 (enExample)
FR2377588B1 (enExample)
DK139397C (enExample)
FR2377301B1 (enExample)
FR2376915B1 (enExample)
DE2753104C2 (enExample)
FR2378166B1 (enExample)
DK142089C (enExample)
DK140675C (enExample)
DK326677A (enExample)
DK352877A (enExample)
BE871991A (enExample)
BG25845A1 (enExample)
BG25810A1 (enExample)
BG23438A1 (enExample)
BG23462A1 (enExample)
BG24331A1 (enExample)
BG25809A1 (enExample)
BE872973A (enExample)
BG26492A1 (enExample)
BG25860A1 (enExample)
BG25855A1 (enExample)
BG25853A1 (enExample)
BG25839A1 (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse